Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 08 2022 - 8:19PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T
cell therapy for the treatment of relapsed or refractory multiple
myeloma (r/r MM), will be presented as a poster at the upcoming
American Association for Cancer Research (AACR) Annual Meeting
2022, held April 8-13, 2022 in New Orleans.
CB-011 is the first allogeneic CAR-T cell therapy immune-cloaked
to prevent both T- and NK-mediated immune cell rejection. This
allogeneic anti-BCMA CAR-T cell therapy is engineered using Cas12a
chRDNA technology to insert a BCMA-specific CAR into the TRAC gene
and armor the cells with an immune cloaking strategy that includes
a knockout of the endogenous B2M gene and site-specific insertion
of a B2M–HLA-E fusion transgene into the B2M gene. Caribou is
conducting Investigational New Drug (IND)-enabling studies to
support a planned IND application submission in 2022 for CB-011 in
r/r MM.
Details of the poster presentation are as follows:
Title: A BCMA-specific allogeneic CAR-T cell
therapy (CB-011) genome-engineered to express an HLA-E fusion
transgene to prevent immune cell rejection
Presenter: Émilie Degagné, Ph.D., Senior Scientist
IDate and Time: Sunday, April 10, 2022, 1:30 –
5:00 pm CTLocation: New Orleans Convention
CenterPresentations and posters will be available for registered
attendees for on-demand viewing on the AACR website on
April 8, 2022 after 1:00 pm ET.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II and Type V CRISPR systems: the
nuclease protein that cuts DNA and the RNA molecule(s) that guide
the nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors. Follow us @CaribouBio
and visit www.cariboubio.com.“Caribou Biosciences” and the Caribou
logo are registered trademarks of Caribou Biosciences, Inc.
Forward-Looking Statements This
press release contains forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s strategy, plans and objectives, and
expectations regarding its clinical and preclinical development
programs, including its timing expectations regarding the foregoing
including future IND application submissions. Management believes
that these forward-looking statements are reasonable as and when
made. However, such forward-looking statements are subject to risks
and uncertainties, and actual results may differ materially from
any future results expressed or implied by the forward-looking
statements. Risks and uncertainties include without limitation the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of current and
future research and development programs, preclinical studies, and
clinical trials, as well as other risk factors described from time
to time in Caribou’s filings with the Securities and Exchange
Commission, including its final prospectus filed on July 23, 2021.
In light of the significant uncertainties in these forward-looking
statements, you should not rely upon forward-looking statements as
predictions of future events. Except as required by law, Caribou
undertakes no obligation to update publicly any forward-looking
statements for any reason.
Caribou Biosciences,
Inc. Contacts: |
Amy Figueroa, CFA |
Investor Relations and Corporate
Communications |
afigueroa@cariboubio.com |
|
Investors: |
Elizabeth Wolffe, Ph.D., and
Sylvia Wheeler |
Wheelhouse LSA |
lwolffe@wheelhouselsa.com |
swheeler@wheelhouselsa.com |
|
Media: |
Greg Kelley |
Ogilvy |
gregory.kelley@ogilvy.com |
617-461-4023 |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024